SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-008228
Filing Date
2024-01-30
Accepted
2024-01-30 16:05:22
Documents
16
Period of Report
2024-01-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2321853d25_8k.htm   iXBRL 8-K 28181
2 EXHIBIT 3.1 tm2321853d25_ex3-1.htm EX-3.1 50546
3 EXHIBIT 3.2 tm2321853d25_ex3-2.htm EX-3.2 122410
  Complete submission text file 0001104659-24-008228.txt   418416

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA avbp-20240130.xsd EX-101.SCH 3015
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE avbp-20240130_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avbp-20240130_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2321853d25_8k_htm.xml XML 3857
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent Biopharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 24578163
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)